Investment analysts at Stifel Nicolaus started coverage on shares of Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) in a research report issued to clients and investors on Friday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $49.00 price target on the stock. Stifel Nicolaus’ target price points to a potential upside of 88.17% from the company’s previous close.
Several other equities analysts also recently issued reports on the stock. Leerink Partners initiated coverage on shares of Oruka Therapeutics in a report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price target for the company. TD Cowen assumed coverage on Oruka Therapeutics in a report on Monday, September 16th. They issued a “buy” rating on the stock. HC Wainwright started coverage on Oruka Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $45.00 price target on the stock. Wedbush started coverage on Oruka Therapeutics in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $40.00 price objective for the company. Finally, Lifesci Capital began coverage on Oruka Therapeutics in a report on Monday, September 16th. They set an “outperform” rating and a $41.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $43.17.
Get Our Latest Stock Analysis on Oruka Therapeutics
Oruka Therapeutics Price Performance
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($25.92) EPS for the quarter. As a group, sell-side analysts anticipate that Oruka Therapeutics will post -1.62 earnings per share for the current fiscal year.
About Oruka Therapeutics
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.
Featured Articles
- Five stocks we like better than Oruka Therapeutics
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- Trading Halts Explained
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- Stock Market Upgrades: What Are They?
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.